Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices
Executive Summary
FDA’s drugs center should identify “best practices” in oncology and antiviral drug reviews that could be applied by less efficient review divisions, such as cardio/renal and neurology, authors of a Manhattan Institute report say.